Amarin to restructure

Over the last several months, the new Amarin Board of Directors and senior management team have conducted a comprehensive review of the business. Vacepa/Vazepa is supported by a wealth of clinical data and backed by strong science that can benefit patients around the world. Amarin continues to generate revenue in the U.S. and maintains a strong cash position. However, the restructuring reflects the need for a thoughtful and significant change in strategy given the Company’s size, resources and challenging operating environment. The Company expects these actions will reduce operating costs by approximately $40 million annually. Amarin’s refocused strategic priorities and restructuring plan focuses on three core areas: i. Maximizing U.S. Cash Flow Through Streamlined Model: Amarin will maintain Vascepa as a cost-effective option to generics while implementing a reduction in force of all U.S. sales force positions and approximately 30% of non-sales roles. Amarin will retain its managed care and trade organization to support these efforts. The Company will continue to explore innovative approaches to driving revenue as well as the timing of an authorized generic version of Vascepa to maintain its leadership position in the icosapent ethyl (IPE) market. ii. European Redesign: Amarin will redesign its commercial infrastructure in Europe to better align with pricing and reimbursement status, commercial potential and progress to date, as well as streamline certain cross-geographic functions and better leverage learnings across countries. In addition, Amarin will continue to advance its pricing and reimbursement activities to drive access in remaining geographies, including those where progress has been delayed. iii. Expanding Upon International Partnerships: Amarin will work on generating revenue from its partnerships in key international markets, including Canada, MENA, China and Australia / New Zealand, and will continue to explore additional partnerships.